Uniqure’s hemophilia B gene therapy program on hold due to cancer diagnosis in treated patient

UniQure, the Dutch gene therapy company, said Monday that it had temporarily halted the clinical development of its hemophilia B treatment after a patient was diagnosed with liver cancer.

The clinical hold, mandated by the Food and Drug Administration, encompasses three ongoing studies of Uniqure’s hemophilia B gene therapy called etranacogene dezaparvovec. Patient dosing in all three studies had already been completed and there is no plan to enroll or treat new patients, the company said.

Shares of Uniqure fell 20% to $36 in early Monday trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In